INNOVATsIONNAYa SAKhAROSNIZhAYuShchAYa TERAPIYa: NOVAYa STRATEGIYa DLYa STAROY PROBLEMY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper is devoted to the innovative strategy for the glucose-lowering therapy with using DPP-4 inhibitors. From the position of the evidence medicine the glycemic and non-glycemic effects, the efficacy, safety, the pathogenic aspects and clinical perspectives are wrote by sitagliptin, the first and the most distinguished representative of the incretins.

Full Text

Restricted Access

References

  1. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008;60(4):470-512.
  2. Анциферов МБ, Аметов АС, Зилов АВ. Ингибиторы ДПП-4: сегодня и завтра. Чего мы ждем от инкретинстимулирующей терапии?// Фарматека 2012. № 7. С. 81-6.
  3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55(6):1577-96.
  4. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.Diabetes Obes Metab 2010;12(5):442-51.
  5. Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30(8):1979-87.
  6. Williams-Herman D, Xu L, Teng R, et al. Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2012;14(1):67-76.
  7. Derosa G, Carbone A, D'Angelo A, et al. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. Expert Opin Pharmacother 2012;13(17):2433-42.
  8. Rathmann W, Kostev K, Gruenberger JB, et al. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonyl-ureas: a primary care database analysis. Diabetes Obes Metab 2013;15(1):55-61.
  9. Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann intern Med 2012;157(9):601-10.
  10. Morgan CL, Poole CD, Evans M, et al. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab 2012;97(12):4605-12.
  11. Currie CJ, Poole CD, Evans M, et al. Mortality and Other important Diabetes-Related Outcomes With insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes. Clin Endocrinol Metab 2013;98(2):668-77.
  12. Pantalone KM, Kattan MW, Yu C, et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 2010;33(6):1224-29.
  13. Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011;13(2):160-68.
  14. Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. int J Clin Pract 2010;64(5):562-76.
  15. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9(2):194-205.
  16. Vora J, Bain SC, Damci T, et al. incretin-based therapy in combination with basal insulin: A promising tactic for the treatment of type 2 diabetes. Diabetes Metab 2012.pii: S1262-3636(12)00120-6.
  17. Hong ES, Khang AR, Yoon JW, et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSi study. Diabetes Obes Metab 2012;14(9):795-802.
  18. Yanai H, Adachi H, Hamasaki H, et al. Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis. J Clin Med Res 2012;4(4):251-58.
  19. Aschner P, Chan J, Owens DR, et al. insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASiE): a multicentre, randomised open-label trial. Lancet 2012;379(9833):2262-69.
  20. Hess K, Marx N, Lehrke M. Cardiovascular disease and diabetes: the vulnerable patient. European Heart Journal Supplements 2012;14(Suppl. B):4-13.
  21. Ravassa S, Zudaire A, Dez J. Glucagon-like peptide 1 and cardiac cell survival. Endocrinol Nutr 2012;59(9):561-69.
  22. Shannon RP, Angeli FC. Beyond glucose: cardiovascular effects of incretins and dipeptidyl peptidase-4 substrates. European Heart Journal 2012;14(Suppl. B):14-21.
  23. Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010;10:7.
  24. Engel SS, Golm GT, Shapiro D, et al. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol 2013;12(1):3.
  25. Theiss HD, Brenner C, Engelmann MG, et al. Safety and efficacy of Sitagliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial infarction (SiTAGRAMi-Trial) - rationale, design and first interim analysis. int J Cardiol 2010;145(2):282-84.
  26. Poitout V. Lipotoxicity impairs incretin signalling. Diabetologia 2013;56(2):231-33.
  27. Derosa G, Ragonesi PD, Arrigo EF. Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation. Fund Clin Pharm 2012;doi:1 0.1111/fcp.12001. [Accepted 03-Sep-2012].
  28. Кособян Е.П., Смирнова О.М. Современные концепции патогенеза неалкогольной жировой болезни печени // Сахарный диабет 2010. № 1. C. 55-65.
  29. iwasaki T, Yoneda M, inamori M, et al. Sitagliptin as a novel treatment agent for non alcoholic Fatty liver disease patients with type diabetes mellitus. Hepatogastroenterology 2011;58(112):2103-105.
  30. iwasaki T, Tomeno W, Yoneda M, et al. Nonalcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin. Hepatogastroenterology 2012;59( 11 7): 1522-25.
  31. Engel SS, Williams-Herman DE, Golm GT, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. int J Clin Pract 2010;64(7):984-90.
  32. Ferreira AJC, Marre M, Barzilai N, et al. Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderateto-Severe Chronic Renal insufficiency. Diabetes Care 2012 Dec 17.[Epub ahead of print].
  33. Chan JC, Scott R, Ferreira AJC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10(7):545-55.
  34. Ferreira AJC, Corry D, Mogensen CE, et al. Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial. Am J Kidney Dis 2013 Jan. doi: 10.1053/j.ajkd.2012.11.043. [Epub ahead of print].
  35. Kissow H, Hartmann B, Holst JJ. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regul Pept 2012;179(1-3):91-100.
  36. Mudaliar S, Henry RR. The incretin hormones: from scientific discovery to practical therapeutics. Diabetologia 2012;55(7):1865-68.
  37. Maiztegui B, Borelli Mi, Madrid VG, et al. Sitagliptin prevents the development of metabolic and hormonal disturbances, increased -cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clin Sci (Lond) 2011;120(2):73-80.
  38. Yeom JA, Kim ES, Park HS, et al. Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice. BMB Rep 2011;44(11):713-18.
  39. Шестакова М.В. Опыт применения ситаглиптина (первого ингибитора ДПП-4) в лечении сахарного диабета 2 типа в Российской Федерации: результаты наблюдательной программы "Диа-Да" // Сахарный диабет 2010. № 3. C. 57-60.
  40. Аметов А.С., Пакус Е.Н. Эффективность и безопасность комбинации метформина и ситаглиптина в лечении больных сахарным диабетом 2 типа с ожирением // Сахарный диабет 2010. № 3. C. 62-5.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies